{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:50:52Z","timestamp":1792522252444,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"publisher","award":["202210337"],"award-info":[{"award-number":["202210337"]}],"id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20252BAC200520"],"award-info":[{"award-number":["20252BAC200520"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232BAB216080"],"award-info":[{"award-number":["20232BAB216080"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232BAB216087"],"award-info":[{"award-number":["20232BAB216087"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20252BAC240438"],"award-info":[{"award-number":["20252BAC240438"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20252BAC240441"],"award-info":[{"award-number":["20252BAC240441"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160459"],"award-info":[{"award-number":["82160459"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503805"],"award-info":[{"award-number":["82503805"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260491"],"award-info":[{"award-number":["82260491"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202869"],"award-info":[{"award-number":["82202869"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160469"],"award-info":[{"award-number":["82160469"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218790","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:15:57Z","timestamp":1787181357000},"page":"218790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["FGFR4 suppresses antitumor immunity and cuproptosis by disrupting CYLD-mediated stabilization of STING and FDX1"],"prefix":"10.1016","volume":"659","author":[{"given":"Hongguang","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiwen","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunye","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinru","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0728-868X","authenticated-orcid":false,"given":"Jun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218790_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218790_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/0008-5472.CAN-20-2426","article-title":"Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with Anti-PD-1 antibodies","volume":"82","author":"Adachi","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218790_bib3","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","article-title":"The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity","volume":"7","author":"Palakurthi","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218790_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","article-title":"Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"17","author":"Chen","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218790_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.05.019","article-title":"First-line pembrolizumab plus lenvatinib for advanced non-clear-cell renal cell carcinoma: updated results from the phase 2 KEYNOTE-B61 trial","author":"Voss","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218790_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.canlet.2026.218790_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.008","article-title":"Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma","author":"Arance","year":"2025","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.canlet.2026.218790_bib8","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2025.05.016","article-title":"Lenvatinib plus pembrolizumab, pemetrexed, and a platinum as first-line therapy for metastatic nonsquamous NSCLC: phase 3 LEAP-006 study","volume":"20","author":"Herbst","year":"2025","journal-title":"J. Thorac. Oncol. : official publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.canlet.2026.218790_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.05.020","article-title":"LEAP-008: lenvatinib plus pembrolizumab for metastatic NSCLC that has progressed after an anti-programmed cell death protein 1 or anti-programmed cell death ligand 1 plus platinum chemotherapy","author":"Leighl","year":"2025","journal-title":"J. Thorac. Oncol. : official publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.canlet.2026.218790_bib10","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.23.02736","article-title":"Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2026.218790_bib11","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO-25-00748","article-title":"Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced metastatic gastroesophageal adenocarcinoma: the phase III, randomized LEAP-015 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2026.218790_bib12","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218790_bib13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218790_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-025-02380-0","article-title":"Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218790_bib15","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1073\/pnas.1621363114","article-title":"cGAS is essential for the antitumor effect of immune checkpoint blockade","volume":"114","author":"Wang","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.canlet.2026.218790_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218790_bib17","article-title":"Trial watch: STING agonists in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218790_bib18","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1158\/1078-0432.CCR-23-1170","article-title":"Correction: phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2026.218790_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11033-024-09418-4","article-title":"STING pathway as a cancer immunotherapy: progress and challenges in activating anti-tumor immunity","volume":"51","author":"Tabar","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.canlet.2026.218790_bib20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41586-019-1000-2","article-title":"Structural basis of STING binding with and phosphorylation by TBK1","volume":"567","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218790_bib21","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202357528","article-title":"RNF144A promotes antiviral responses by modulating STING ubiquitination","volume":"24","author":"Yang","year":"2023","journal-title":"EMBO Rep."},{"key":"10.1016\/j.canlet.2026.218790_bib22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41423-019-0205-5","article-title":"STING palmitoylation as a therapeutic target","volume":"16","author":"Hansen","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2026.218790_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.immuni.2016.08.014","article-title":"Sumoylation promotes the stability of the DNA sensor cGAS and the adaptor STING to regulate the kinetics of response to DNA virus","volume":"45","author":"Hu","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218790_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007435","article-title":"The deubiquitinase CYLD is a specific checkpoint of the STING antiviral signaling pathway","volume":"14","author":"Zhang","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.canlet.2026.218790_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218790_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41419-025-07621-0","article-title":"TMEM160 inhibits KEAP1 to suppress ferroptosis and induce chemoresistance in gastric cancer","volume":"16","author":"Huang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218790_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12964-024-01541-w","article-title":"TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer","volume":"22","author":"Dai","year":"2024","journal-title":"Cell Commun. Signal. : CCS"},{"key":"10.1016\/j.canlet.2026.218790_bib28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nature14156","article-title":"Mitochondrial DNA stress primes the antiviral innate immune response","volume":"520","author":"West","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218790_bib29","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218790_bib30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.canlet.2026.218790_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.13272","article-title":"Type I interferon and cancer","volume":"321","author":"Holicek","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2026.218790_bib32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2026.218790_bib33","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218790_bib34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41590-021-00896-3","article-title":"The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFN-\u03b2 pathway","volume":"22","author":"Takahashi","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218790_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117632","article-title":"STING inhibitors and degraders: potential therapeutic agents in inflammatory diseases","volume":"291","author":"Wu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2026.218790_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218790_bib37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molcel.2009.04.031","article-title":"Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation","volume":"34","author":"Hutti","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218790_bib38","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0092-8674(00)80252-4","article-title":"A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras\/MAPK signaling pathway","volume":"89","author":"Kouhara","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218790_bib39","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.2147\/CMAR.S268216","article-title":"CYLD promotes apoptosis of nasopharyngeal carcinoma cells by regulating NDRG1","volume":"12","author":"Lin","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.canlet.2026.218790_bib40","doi-asserted-by":"crossref","first-page":"14422","DOI":"10.1074\/jbc.M114.547547","article-title":"Toll-like receptor-mediated down-regulation of the deubiquitinase cylindromatosis (CYLD) protects macrophages from necroptosis in wild-derived mice","volume":"289","author":"Schworer","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218790_bib41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41419-024-06464-5","article-title":"CYLD regulates cell ferroptosis through Hippo\/YAP signaling in prostate cancer progression","volume":"15","author":"Gu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218790_bib42","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1021\/jacsau.4c00712","article-title":"Signaling mechanism of cuproptosis activating cGAS-STING immune pathway","volume":"4","author":"Zhu","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.canlet.2026.218790_bib43","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1038\/s41467-023-42025-8","article-title":"Lactylation of METTL16 promotes cuproptosis via m(6)A-modification on FDX1 mRNA in gastric cancer","volume":"14","author":"Sun","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218790_bib44","article-title":"AKT1 phosphorylates FDX1 to promote cuproptosis resistance in triple-negative breast cancer","volume":"12","author":"Sun","year":"2025","journal-title":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.canlet.2026.218790_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103722","article-title":"LncRNA PVT1 promotes cuproptosis through transcriptional activation of FDX1 in colorectal cancer","volume":"85","author":"Ma","year":"2025","journal-title":"Redox Biol."},{"key":"10.1016\/j.canlet.2026.218790_bib46","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell Death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218790_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2021619","article-title":"Immunomodulation via FGFR inhibition augments FGFR1 targeting T cell based antitumor immunotherapy for head and neck squamous cell carcinoma","volume":"11","author":"Kono","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218790_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","article-title":"FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2","volume":"79","author":"Xie","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218790_bib49","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","article-title":"Copper homeostasis and cuproptosis in health and disease","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218790_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1646890","article-title":"Mechanism and application of copper-based nanomedicines in activating tumor immunity through oxidative stress modulation","volume":"16","author":"Xia","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218790_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218192","article-title":"Copper orchestrates triple-negative breast cancer progression via the STEAP3-dependent CDK16-JAK1 activation","volume":"639","author":"Duan","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218790_bib52","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41467-022-30217-7","article-title":"N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer","volume":"13","author":"Zou","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218790_bib53","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:34:23Z","timestamp":1789108463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526005549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":53,"alternative-id":["S0304383526005549"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218790","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR4 suppresses antitumor immunity and cuproptosis by disrupting CYLD-mediated stabilization of STING and FDX1","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218790"}}